iShares Biotechnology ETF $IBB Stake Lifted by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division boosted its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 296,500.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,830 shares of the financial services provider’s stock after buying an additional 14,825 shares during the period. Central Pacific Bank Trust Division’s holdings in iShares Biotechnology ETF were worth $2,503,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in IBB. BNP Paribas Financial Markets grew its position in shares of iShares Biotechnology ETF by 313.2% during the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock worth $276,526,000 after acquiring an additional 1,451,820 shares during the last quarter. JPMorgan Chase & Co. lifted its position in iShares Biotechnology ETF by 27.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after purchasing an additional 226,852 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in iShares Biotechnology ETF during the 3rd quarter valued at about $65,083,000. Barclays PLC boosted its stake in iShares Biotechnology ETF by 6.7% during the 3rd quarter. Barclays PLC now owns 416,191 shares of the financial services provider’s stock valued at $60,085,000 after purchasing an additional 26,032 shares during the period. Finally, Employees Retirement System of Texas bought a new position in iShares Biotechnology ETF in the 2nd quarter worth about $25,049,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ:IBB opened at $161.65 on Friday. The firm’s 50 day moving average is $171.97 and its two-hundred day moving average is $163.30. iShares Biotechnology ETF has a 52 week low of $107.43 and a 52 week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Investors of record on Tuesday, March 17th were issued a $0.1218 dividend. This represents a $0.49 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Tuesday, March 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.